Form 4 Kite Pharma, Inc. For: Oct 03 Filed by: Wiezorek Jeffrey
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
BTIG Affirms Kite Pharma (KITE) at 'Neutral' as ZUMA-6 Begins
October 6, 2016 11:45 AM EDTBTIG affirms Kite Pharma, Inc. (Nasdaq: KITE) with a Neutral rating after the company announced the first patient was enrolled in ZUMA-6, a Phase 1b/2 clinical study of KTE-C19 in combination with atezolizumab, Genentechs anti-PD-L1 cancer immunotherapy.
Analyst Dane Leone commented today: The... More
